Sutter Health Research Enterprise
3838 California Street
San Francisco, CA, 94118
(415) 751-1847
ClinicalResearch@sutterhealth.org
Sutter Health Research Enterprise
3838 California Street
San Francisco, CA, 94118
(415) 751-1847
ClinicalResearch@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Locally Advanced or Metastatic (Merck 7339-007)
Study of Olaparib in Combination With Pembrolizumab in the Treatment of HRRm and/or
HRD Positive Advanced Cancer
Investigators: Lejla Delic MD, Kevin Kim MD, Wei Wang MD
Status: Active, Recruiting
Locally Advanced or Metastatic (Roche YO40482)
Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab
to Patients With Advanced Platinum-sensitive Ovarian Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic or Locally Advanced (Agenus GOG 3028)
Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line
Cervical Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Recruiting
Novocure Innovate3
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel
for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / IN
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Recruiting